D C Weir, R I Gove, A S Robertson, P Sherwood Burge Abstract One hundred and twenty seven adults considered on clinical grounds to have non-asthmatic chronic airflow obstruction entered a randomised, double blind, placebo controlled, crossover trial comparing the physiological response to inhaled beclomethasone dipropionate 500 jg thrice daily with oral prednisolone 40 mg a day, both given for two weeks. One hundred and seven patients completed the study. Response was assessed as change in FEV, and FVC measured on the last treatment day, and as change in mean peak expiratory flow (PEF) over the final seven days of treatment from home PEF recordings performed five times daily. A full response to treatment was defined as an increase in FEV or FVC, or an increase in mean daily PEF over the final seven days of treatment, of at least 20% from baseline values. An improvement in one measurement ofat least 15%, or of 10% in any two measurements, was defined as a partial treatment response. Response to placebo showed a significant order effect, suggesting a carry over effect of active treatment of at least three weeks. Response to active treatment was therefore related to initial baseline values, and compared with placebo by considering responses in the first treatment phase only. A full response to oral prednisolone (16138) was significantly more common than to placebo (3/35 The smaller dose of each drug was given by a metered dose inhaler and the larger dose by an Inspiron mini-Neb nebuliser, the drug being nebulised to dryness. Bronchial responsiveness to inhaled histamine was determined by the method of Cockroft et al,7 on the second baseline visit if the FEV, was above 0-6 1.
After the second baseline visit patients were asked to measure peak expiratory flow rate (with a mini Wright's peak flow meter) four hourly during waking hours at home, and record the best of at least three attempts with the best two within 20 1/min. All baseline values were obtained during the two weeks before the first treatment phase and mean daily PEF was calculated over the final seven days of this period. Diurnal variation in PEF was calculated from the same readings as mean daily maximum PEF (mean daily maximum PEF minus mean daily minimum PEF divided by mean daily PEF). Baseline data were compared by means of a paired or unpaired Student's t test for normally distributed data or a Wilcoxon signed rank or rank sum test for data not normally distributed. Treatment order effect was assessed by a logit regression on proportions, the GLIM statistical package being used.8 Active treatment response rates were compared by McNemar's test, and the responses to the treatments given during the first phase by a x2 test.
All predicted values are derived from published equations.9
Results
Of the 127 patients who entered the study, 107 completed the protocol. Eleven patients defaulted at subsequent visits: six had an infective exacerbation of their disease, one died of an unrelated cause during the run in period, and two had complications during the oral prednisolone phase (exacerbation of chronic duodenal ulceration in one, left ventricular failure in the other). The mean age (63 years) and the FEV, and FVC (390% and 70% predicted) of those withdrawn were similar to the mean values in patients who completed the study. The baseline lung function characteristics of the study group are given in table 1 and  details of smoking and atopy in table 2 .
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There are no significant differences between groups. The responses of individual patients to oral prednisolone and inhaled beclomethasone are shown in figures 1-3 for FEV,, FVC, and PEF. The slope of the least squares regression line for each plot is significantly different from the line of identity, indicating a greater effect of prednisolone on each measurement.
A full response to an active treatment occurred on 65 occasions. The measurements in which a response was seen on these occasions are shown in the Venn diagram (fig 4) . A full response was seen in all three measurements on only seven occasions and in two of the measurements on a further 17 occasions; in most cases (41) a full response was seen in only one measurement.
In the 44 patients who had a full response to prednisolone or beclomethasone the change in the measurement showing the greatest response was expressed as a percentage of the patient's predicted value, a measure independent of baseline FEV, (fig 5) . The responders remained distinct from the nonresponders.
The mean reversibility in FEV, in response to 10 mg inhaled salbutamol was 18%, expressed as a percentage of the prebronchodilator value (table 1) . If expressed in terms of potential reversibility-that is, as a percentage of the predicted minus the prebronchodilator value-the mean improvement was 15 5%. Only 13 patients showed an increase in this measurement of over 500/0, indicating that most of the patients had relatively fixed airflow obstruction. Response to prednisolone or beclomethasone or both in the 13 "reversible" patients (4/13) was similar to that seen in the "irreversible" patients (40/94; x2 = 0-64 NS).
Cigarette consumption in the patients varied from zero to 2520 cigarette years, with a mean of 761 cigarette years (table 2) . Twelve patients claimed to be life long non-smokers. Eighty one patients admitted to a cigarette consumption in excess of 400 cigarette years. Full and partial responses to prednisolone or beclomethasone or both were similar in this group of heavier smokers (39/81) and in the remaining patients (11/26; x2 = 0.57; NS). minute walking distances improved significantly with both active treatments in the steroid responsive patients, whereas no effect was seen with treatment in the non-responders. Visual analogue scores showed a wide variation and, although they improved in all response groups with treatment, the changes were not significant.
A further possible criticism of our results is that because of the "soft" entry criteria we inadvertently included patients with missed asthma in the study population. The criteria were chosen to reflect clinical practice and only where the physician was unsure of the benefit of steroid treatment-that is, where asthma was not present-was a patient entered. Those who had had respiratory disease in childhood were excluded, which eliminated many patients with asthma. Not all patients were current smokers or ex-smokers, although most had smoked heavily. Many patients showed a degree of reversibility in response to inhaled bronchodilators that was within the "asthmatic" range of 20 0o or more of the prebronchodilator FEV,.
This, however, is a misleading measure of reversibility in patients with a low prebronchodilator FEV,. A better indication of reversibility is obtained by considering the reversibility as a percentage of the predicted FEV, minus the prebronchodilator value (table  1) . Most of our patients had largely irreversible airflow obstruction. Response to one or both corticosteroid treatments was not related to past cigarette consumption or to reversibility in response to inhaled salbutamol, suggesting that our patients were predominantly nonasthmatic. The degree of response to corticosteroids shown in figure 5 shows a unimodal distribution, again suggesting that the patients came from a single disease group. Hence we believe that most of the patients were not asthmatic, and that our findings are relevant to patients diagnosed as having chronic airflow obstruction in clinical practice. 
